Summary of all highly purified HSC clones tested and average HSC expansion in vitro achieved in response to forced expression of NUP98-HOXA10hd
| Phenotype tested . | CD45+lin−Rho−SP . | E-SLAM . |
|---|---|---|
| No. of NUP98-HOXA10hd HSC clones tested | 28 | 17 |
| No. of expanded HSC clones | 25 | 15 |
| Minimum cell dose (fraction of culture) transplanted | 1/500 or 1/1000, or 1/2000 or 1/5000 | 1/500 or 1/1000 |
| Average minimum HSC expansion in vitro estimated (LD not reached) | > 806-fold | > 942-fold |
| Range based on ± SEM | 381 ± 1730 | 425 ± 2110 |
| Average HSC expansion in vitro documented (LD reached) | 2520-fold | |
| Range based on ± SEM | 1140 ± 5720 |
| Phenotype tested . | CD45+lin−Rho−SP . | E-SLAM . |
|---|---|---|
| No. of NUP98-HOXA10hd HSC clones tested | 28 | 17 |
| No. of expanded HSC clones | 25 | 15 |
| Minimum cell dose (fraction of culture) transplanted | 1/500 or 1/1000, or 1/2000 or 1/5000 | 1/500 or 1/1000 |
| Average minimum HSC expansion in vitro estimated (LD not reached) | > 806-fold | > 942-fold |
| Range based on ± SEM | 381 ± 1730 | 425 ± 2110 |
| Average HSC expansion in vitro documented (LD reached) | 2520-fold | |
| Range based on ± SEM | 1140 ± 5720 |
LD indicates limiting dilution.